/ /

  • linkedin
  • Increase Font
  • Sharebar

    Ziv-aflibercept for DME provides BCVA gains, lower dosing burden


    For the subgroup of eyes with initial BCVA of 20/30 to 20/40, all treatments were associated with a statistically significant improvement in BCVA and a statistically significant reduction in CMT at 1 year. The improvement in BCVA and in CMT was significantly greater with ziv-aflibercept 2.5 mg versus 1.25 mg. There were no significant differences comparing the ziv-aflibercept groups with bevacizumab.

    For eyes with initial BCVA ≤20/50, all treatments resulted in significant reduction in CMT at 1 year, and the effect was significantly greater in eyes treated with ziv-aflibercept 2.5 mg versus bevacizumab.

    Dr. Soheilian has no relevant financial interests to disclose.


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results